brexucabtagene autoleucel
gilead sciences
['leukemia', 'leusm', 'zuma-3']
congress #asco22 | talks through the longer follow-up results of the zuma-3 trial of kte-x19 in patients with r/r b-all (n=55). median follow-up of 26.8 months cr/cri rate 71%. 11 went on to allo-sct with a subsequent median dor of 14.6 months #leusm #leukemia 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm